Abstract
We examined risk of second cancer and late mortality in a population-based Australian cohort of 717 pediatric allogeneic stem cell transplant (HSCT) recipients treated for a malignant disease during 1982–2007. Record linkage with population-based death and cancer registries identified 17 second cancers at a median of 7.9 years post HSCT; thyroid cancer being the most common malignancy (n=8). The cumulative incidence of second cancer was 8.7% at follow-up, and second cancers occurred 20 times more often than in the general population (standardised incidence ratio 20.3, 95% confidence interval (CI)=12.6–32.7). Transplantation using radiation-based conditioning regimens was associated with increased second cancer risk. A total of 367 patients survived for at least 2 years post HSCT and of these 44 (12%) died at a median of 3.1 years after HSCT. Relapse was the most common cause of late mortality (n=32). The cumulative incidence of late mortality was 14.7%. The observed rate of late mortality was 36 times greater than in the matched general population (standardised mortality ratio 35.9, 95% CI=26.7–48.3). Recipients who relapsed or who had radiation-based conditioning regimens were at higher risk of late mortality. Second cancers and late mortality continue to be a risk for pediatric patients undergoing HSCT, and these results highlight the need for effective screening and survivorship programs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Socie G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348–357.
Baker KS, Defor TE, Burns LJ, Ramsay NK, Neglia JP, ROBISON LL . New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358.
Schechter T, Pole JD, Darmawikarta D, Doyle J, Ali M, Egeler M et al. Late mortality after hematopoietic SCT for a childhood malignancy. Bone Marrow Transplant 2013; 48: 1291–1295.
Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Ma DD, Moore JJ et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007; 13: 905–912.
Bhatia S, Louie AD, Bhatia R, O'Donnell MR, Fung H, Kashyap A et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464–471.
Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175–1183.
Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639.
Cohen A, Rovelli A, Merlo DF, Van Lint MT, Lanino E, Bresters D et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol 2007; 25: 2449–2454.
Cohen A, Rovelli A, Van Lint MT, Merlo F, Gaiero A, Mulas R et al. Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood. Bone Marrow Transplant 2001; 28: 1125–1128.
Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386–392.
Kolb HJ, Socie G, Duell T, Van Lint MT, Tichelli A, Apperley JF et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738–744.
Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904.
Hemminki K, Jiang Y, Steineck G . Skin cancer and non-Hodgkin’s lymphoma as second malignancies: markers of impaired immune function? Eur J Cancer 2003; 39: 223–229.
Guerin S, Dupuy A, Anderson H, Shamsaldin A, Svanh-Tapper G, Moller T et al. Radiation dose as a risk factor for malignant melanoma following childhood cancer. Eur J Cancer 2003; 39: 2379–2386.
Corpron CA, Black T, Ross MI, Herzog CS, Ried HL, Lally KP et al. Melanoma as a second malignant neoplasm after childhood cancer. Am J Surg 1996; 172: 459–462.
Chou RH, Wong GB, Kramer JH, Wara DW, Matthay KK, Crittenden MR et al. Toxicities of total-body irradiation for pediatric bone marrow transplantation. Intl J Radiat Oncol Biol Phys 1996; 34: 843–851.
Ferry C, Gemayel G, Rocha V, Labopin M, Esperou H, Robin M et al. Long-term outcomes after allogeneic stem cell transplantation for children with haematological malignancies. Bone Marrow Transplant 2007; 40: 219–224.
Perkins JL, Kunin-Batson AS, Youngren NM, Ness KK, Ulrich KJ, Hansen MJ et al. Long-term follow-up of children who underwent hematopoietic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer 2007; 49: 958–963.
Davies SM, Ramsay NKC, Klein JP, Weisdorf DJ, Bolwell B, Cahn J-Y et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340–347.
Boulad F, Steinherz P, Reyes B, Heller G, Gillio AP, Small TN et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999; 17: 197–207.
Eapen M, Ahn KW, Orchard PJ, Cowan MJ, Davies SM, Fasth A et al. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transplant 2012; 18: 1438–1445.
Ponce DM, Zheng J, Gonzales AM, Lubin M, Heller G, Castro-Malaspina H et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1316–1326.
Eapen M, Rubinstein P, Zhang M-J, Stevens C, Kurtzberg J, Scaradavou A et al. Outcomes of transplantation of unrelated donor umbilical cord and bone marrow in children with acute leukemia: a comparison study. Lancet 2007; 369: 1947–1954.
Gluckman E, Rocha V, on behalf of the EBMT Paediatirc, Acute Leukemia Working Parties and Eurocord. Indications and results of cord blood transplant in children with leukemia. Bone Marrow Transplant 2008; 41: S80–S82.
Sauter C, Barker JN . Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies. Curr Opin Hematol 2008; 15: 568–57.
Acknowledgements
This work was supported by a project grant from the National Health and Medical Research Council (NHMRC ID568775), the Arrow Bone Marrow Transplant Foundation, Australia, an NHMRC Career Development Fellowship (ID1023159 to CMV) and a Cancer Institute New South Wales Career Development Fellowship (ID 10/CDF/2-42 to CMV).
Author contributions
LJA and CMV designed the research. TAO’B and LJA coordinated the research. RELM and BD analysed the data. ASN, LJA, CMV, RELM, BD, LW, IN-S and TAO’B interpreted the data. ASN, CMV and TAO’B wrote the manuscript and all authors contributed to and approved the final manuscript.
Members of CAST Study Group
L Ashton (Research Portfolio, University of Sydney), RE Le Marnsey (Cancer Institute Australia, New South Wales); A Dodds, J Tan, I Bilmon (St Vincent’s Hospital, New South Wales); L Wilcox, I Nivison-Smith, D Aarons, S Tran (ABMTRR), C Vajdic (University of New South Wales); J Gibson A Johnston (Royal Prince Alfred Hospital, New South Wales); M Greenwood, M Forbes (Royal North Shore Hospital, New South Wales); M Hertzberg, G Huang (Westmead Hospital, New South Wales); A Spencer, J Muirhead (Alfred Hospital, Victoria); J Szer, K Mason (Royal Melbourne Hospital, Victoria); I Lewis, C To (Royal Adelaide Hospital, South Australia); S Durrant, R Western (Royal Brisbane and Women’s Hospital, Queensland); P Cannell, S Buffery (Royal Perth Hospital, Western Australia); T O’Brien, C Oswald, AS Nelson (Sydney Children’s Hospital, New South Wales); P Shaw, L Pearson (Children’s Hospital at Westmead, New South Wales); K Tiedemann, M Scoyne (Royal Children’s Hospital Melbourne, Victoria); C Fraser, J Seljak (Royal Children’s Hospital Brisbane, Queensland); C Cole, K Rowland, H Gough (Princess Margaret Hospital for Children, Western Australia); H Tapp, N Green (Women and Children’s Hospital, South Australia). Data collectors: RE Le Marsney, A Moa, J McRae and M Jenkins (Children’s Cancer Institute Australia, New South Wales); J Hicks (Royal Melbourne Hospital, Victoria); K Chaplin (Royal Adelaide Hospital, South Australia).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Nelson, A., Ashton, L., Vajdic, C. et al. Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy. Leukemia 29, 441–447 (2015). https://doi.org/10.1038/leu.2014.203
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.203
This article is cited by
-
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL – long-term follow-up from the prospective ALL-SCT 2003 trial
Leukemia (2022)
-
“Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation”
Journal of Cancer Research and Clinical Oncology (2019)
-
Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2
Leukemia (2018)
-
Secondary solid cancer screening following hematopoietic cell transplantation
Bone Marrow Transplantation (2015)